New combo therapy aims to tame tough prostate cancer
NCT ID NCT04592237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor (niraparib) alone or with cetrelimab to see which better controls the cancer. The study involves 120 participants and aims to measure how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabazitaxel, carboplatin, cetrelimab, niraparib
What this could lead to
If successful, this could offer a new treatment option that helps control aggressive prostate cancer that has spread, potentially extending the time before the disease worsens.
What could go wrong
This is an early phase 2 trial with only 120 participants, so results may not apply to all patients. The combination of drugs can cause significant side effects, and it is not yet known if adding cetrelimab maintenance improves outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States